CN105434790A - Oral pharmaceutical composition used for treating ischemic cerebrovascular disease, and preparation method thereof - Google Patents
Oral pharmaceutical composition used for treating ischemic cerebrovascular disease, and preparation method thereof Download PDFInfo
- Publication number
- CN105434790A CN105434790A CN201510960039.2A CN201510960039A CN105434790A CN 105434790 A CN105434790 A CN 105434790A CN 201510960039 A CN201510960039 A CN 201510960039A CN 105434790 A CN105434790 A CN 105434790A
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- combination
- rhizoma dioscoreae
- oral medication
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000000302 ischemic effect Effects 0.000 title claims abstract description 25
- 238000002360 preparation method Methods 0.000 title claims description 9
- 208000026106 cerebrovascular disease Diseases 0.000 title abstract description 4
- 239000008203 oral pharmaceutical composition Substances 0.000 title abstract 5
- 241001116389 Aloe Species 0.000 claims abstract description 19
- 241000005787 Cistanche Species 0.000 claims abstract description 19
- 241000237903 Hirudo Species 0.000 claims abstract description 19
- 235000011399 aloe vera Nutrition 0.000 claims abstract description 19
- 239000008187 granular material Substances 0.000 claims abstract description 19
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims abstract description 19
- 239000007788 liquid Substances 0.000 claims abstract description 10
- 239000006187 pill Substances 0.000 claims abstract description 6
- 239000002775 capsule Substances 0.000 claims abstract description 3
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 3
- 239000003826 tablet Substances 0.000 claims abstract description 3
- 239000003814 drug Substances 0.000 claims description 51
- 229940079593 drug Drugs 0.000 claims description 32
- 239000000843 powder Substances 0.000 claims description 26
- 241000756943 Codonopsis Species 0.000 claims description 25
- 239000009636 Huang Qi Substances 0.000 claims description 25
- 235000003143 Panax notoginseng Nutrition 0.000 claims description 25
- 241000180649 Panax notoginseng Species 0.000 claims description 25
- 229940126701 oral medication Drugs 0.000 claims description 24
- 239000000203 mixture Substances 0.000 claims description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
- 239000000796 flavoring agent Substances 0.000 claims description 10
- 235000019634 flavors Nutrition 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 10
- 238000003809 water extraction Methods 0.000 claims description 7
- 239000002671 adjuvant Substances 0.000 claims description 3
- -1 concentrated Substances 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 239000006196 drop Substances 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims 1
- 239000008280 blood Substances 0.000 abstract description 9
- 210000004369 blood Anatomy 0.000 abstract description 9
- 239000000463 material Substances 0.000 abstract description 3
- 241000382455 Angelica sinensis Species 0.000 abstract 1
- 241000045403 Astragalus propinquus Species 0.000 abstract 1
- 244000037364 Cinnamomum aromaticum Species 0.000 abstract 1
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 abstract 1
- 241000007126 Codonopsis pilosula Species 0.000 abstract 1
- 235000009917 Crataegus X brevipes Nutrition 0.000 abstract 1
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 abstract 1
- 235000009685 Crataegus X maligna Nutrition 0.000 abstract 1
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 abstract 1
- 235000009486 Crataegus bullatus Nutrition 0.000 abstract 1
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 abstract 1
- 235000009682 Crataegus limnophila Nutrition 0.000 abstract 1
- 235000004423 Crataegus monogyna Nutrition 0.000 abstract 1
- 240000000171 Crataegus monogyna Species 0.000 abstract 1
- 235000002313 Crataegus paludosa Nutrition 0.000 abstract 1
- 235000009840 Crataegus x incaedua Nutrition 0.000 abstract 1
- 244000303040 Glycyrrhiza glabra Species 0.000 abstract 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 abstract 1
- 235000017443 Hedysarum boreale Nutrition 0.000 abstract 1
- 235000007858 Hedysarum occidentale Nutrition 0.000 abstract 1
- 244000131316 Panax pseudoginseng Species 0.000 abstract 1
- 235000003181 Panax pseudoginseng Nutrition 0.000 abstract 1
- 235000006533 astragalus Nutrition 0.000 abstract 1
- 235000013399 edible fruits Nutrition 0.000 abstract 1
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 abstract 1
- 230000003014 reinforcing effect Effects 0.000 abstract 1
- 238000013268 sustained release Methods 0.000 abstract 1
- 239000012730 sustained-release form Substances 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 238000012360 testing method Methods 0.000 description 6
- 239000004677 Nylon Substances 0.000 description 5
- 210000000269 carotid artery external Anatomy 0.000 description 5
- 210000004004 carotid artery internal Anatomy 0.000 description 5
- 229920001778 nylon Polymers 0.000 description 5
- 208000006011 Stroke Diseases 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 3
- 230000002490 cerebral effect Effects 0.000 description 3
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 2
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 2
- 241000721047 Danaus plexippus Species 0.000 description 2
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 2
- 238000011047 acute toxicity test Methods 0.000 description 2
- 210000002551 anterior cerebral artery Anatomy 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 235000019219 chocolate Nutrition 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 238000009499 grossing Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 229960000715 nimodipine Drugs 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000007204 Brain death Diseases 0.000 description 1
- 206010008089 Cerebral artery occlusion Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 241000406668 Loxodonta cyclotis Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000005374 Poisoning Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 201000007201 aphasia Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 210000001168 carotid artery common Anatomy 0.000 description 1
- 230000003727 cerebral blood flow Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 208000017561 flaccidity Diseases 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000007373 indentation Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 210000003657 middle cerebral artery Anatomy 0.000 description 1
- 201000007309 middle cerebral artery infarction Diseases 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000010410 reperfusion Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/62—Leeches; Worms, e.g. cestodes, tapeworms, nematodes, roundworms, earth worms, ascarids, filarias, hookworms, trichinella or taenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/233—Bupleurum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/344—Codonopsis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/64—Orobanchaceae (Broom-rape family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/69—Polygalaceae (Milkwort family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/734—Crataegus (hawthorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/804—Rehmannia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/886—Aloeaceae (Aloe family), e.g. aloe vera
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/894—Dioscoreaceae (Yam family)
- A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses an oral pharmaceutical composition used for treating ischemic cerebrovascular disease. The oral pharmaceutical composition is prepared from, by weight, 60 to 180 parts of astragalus membranaceus, 40 to 120 parts of codonopsis pilosula, 40 to 110 parts of angelica sinensis, 20 to 60 parts of herba cistanche, 10 to 50 parts of hawthorn fruit, 10 to 50 parts of aloe, 10 to 40 parts of radix polygalae, 10 to 50 parts of radix paeoniae alba, 10 to 50 parts of radix bupleuri, 5 to 30 parts of cassia twig, 10 to 50 parts of rhizoma dioscoreae, 10 to 50 parts of radix rehmanniae, 10 to 50 parts of pseudo-ginseng, 10 to 50 parts of hirudo, and 10 to 50 parts of honey-fried licorice root. The oral pharmaceutical composition is capable of reinforcing qi and nourishing blood, and removing stasis and dredging collaterals. Common auxiliary materials can be added, and the oral pharmaceutical composition can be made into clinically acceptable tablet, granule, pill, capsule, dripping pill, sustained release agent, and oral liquid.
Description
Technical field
The present invention relates to drug world, specifically, relate to a kind of combination of oral medication for the treatment of ischemic cerebrovascular and preparation method thereof.
Background technology
Along with Cerebral Vascular Disease rate constantly increases, generally acknowledge that it is one of healthy most important disease of harm humans at present, in 57 countries of World Health Organization's investigation, die from cerebrovascular patient account for 11.3%, wherein 40 national cerebrovascular row cause of the death front threes.Owing to strengthening the change of control to blood circulation diseases and residents'living habit over nearly 20 years, western developed country and Japanese mortality of cerebrovascular disease rate have downward trend, especially Japan, according to Japanese health ministry 1987 " population vital statistics ", from 1960,1970, within 1980 to 1985 years, Stroke Death order is the 3rd from the 1st potential drop.But Eastern Europe, West Europe, that some countries and regions, Asia comprise China's situation is still serious, according to Ministry of Public Health 1990-1991 and 1,993 one nineteen ninety-five urban and urual areas of whole country's principal disease cause of death statistics, cerebrovascular accounts for the 2nd (1990,1991,1993) the and 1st (1994,1995), its high mortality and high disability rate, cause great economic loss.The U.S. in 1986 estimates about there are 500,000 people's morbidities, and 14.78 ten thousand people are dead, and living patients needs Medicare to reach 2,020,000 people.The medical care expenses of average each Patients with Cerebral Infarction is 8,000 one 16500 dollars, and these still do not comprise the ancillary cost (as nursing etc.) of sequela.
According to statistics, China's Cerebral Haemorrhage Invasion Rate is 1,20/,100,000 one 180,/10 ten thousand people, and annual new apoplexy 1,500,000 people, Stroke Death rate occupies second place of the world (mortality rate 80,/10 ten thousand-120,/10 ten thousand people), thus, every year because of Stroke Death number about 1,200,000.Brain death rate so and its medical care expenses quite surprising, give society and family cause white elephant.At present, there is no the sickness rate of data proof cerebrovascular, mortality rate and total prevalence rate has downward trend, and along with mankind's aging, the status of cerebrovascular is gradually in rising trend.
Clinically, the treatment meanss such as doctor trained in Western medicine many employings thrombolytic therapy and anticoagulant therapy, these methods have certain curative effect when just morbidity, but can cause the side effect such as subcutaneous hemorrhage, gastrointestinal hemorrhage, cerebral hemorrhage in the long-term ischemic cerebrovascular catabasis treatment of patient.
The Traditional chinese medicine medicament of current existing treatment ischemic cerebrovascular is in clinical practice, but the oral formulations for the treatment of ischemic cerebrovascular seldom has special in the paracmastic medicine of ischemic cerebrovascular at present.
Summary of the invention
Object of the present invention is exactly in order to avoid providing a kind of toxicity low with the shortcoming and defect overcoming prior art, convenient oral, the combination of oral medication of eutherapeutic treatment ischemic cerebrovascular.
A kind of combination of oral medication for the treatment of ischemic cerebrovascular involved in the present invention, it is mainly made up of the crude drug Radix Astragali, Radix Codonopsis, Radix Angelicae Sinensis, Herba Cistanches, Fructus Crataegi, Aloe, Radix Polygalae, the Radix Paeoniae Alba, Radix Bupleuri, Ramulus Cinnamomi, Rhizoma Dioscoreae, Radix Rehmanniae, Radix Notoginseng, Hirudo, Radix Glycyrrhizae Preparata.
The present invention is used for the paracmastic treatment of ischemic cerebrovascular, the Radix Astragali, and Radix Codonopsis is monarch drug, invigorating primordial QI and rise flaccidity give up, make the prosperous blood of gas, Radix Angelicae Sinensis, Radix Notoginseng, Hirudo is ministerial drug, and nourish heart blood, blood circulation promoting and blood stasis dispelling, Radix Rehmanniae, Herba Cistanches the kidney invigorating, Radix Polygalae is calmed the nerves Fructus Alpiniae Oxyphyllae, Radix Bupleuri, Radix Paeoniae Alba dispersing the stagnated live-QI to relieve the stagnation of QI are adjuvant drug altogether, Fructus Crataegi, Rhizoma Dioscoreae, and Aloe spleen invigorating benefit intestinal is for making medicine, separately add Radix Glycyrrhizae Preparata invigorating middle warmer, Ramulus Cinnamomi the meridian dredging, be jointly in harmonious proportion the property of medicine.
Benefiting QI and nourishing blood of the present invention, eliminating blood stasis and smoothing collaterals.The paracmastic treatment of ischemic cerebrovascular for venation block, disease meeting hemiplegia, the silent aphasia of sound, crooked mouth and tongue, hemianesthesia, shortness of breath and fatigue, cardiopalmus, color Koushi be white, from sweating, brothers' swelling, constipation, white and greasy fur or have indentation, deep-thready pulse person.
The consumption of its drug component of pharmaceutical composition of the present invention is also through inventor and gropes in a large number to sum up and draw
Treat a combination of oral medication for ischemic cerebrovascular, composition and the weight portion of making the crude drug of this medicine are: Radix Astragali 60-180 part, Radix Codonopsis 40-120 part, Radix Angelicae Sinensis 40-110 part, Herba Cistanches 20-60 part, Fructus Crataegi 10-50 part, Aloe 10-50 part, Radix Polygalae 10-40 part, Radix Paeoniae Alba 10-50 part, Radix Bupleuri 10-50 part, Ramulus Cinnamomi 5-30 part, Rhizoma Dioscoreae 10-50 part, Radix Rehmanniae 10-50 part, Radix Notoginseng 10-50 part, Hirudo 10-50 part, Radix Glycyrrhizae Preparata 10-50 part.
Treat a combination of oral medication for ischemic cerebrovascular, the composition of crude drug and weight portion can also be: Radix Astragali 80-160 part, Radix Codonopsis 60-110 part, Radix Angelicae Sinensis 50-100 part, Herba Cistanches 30-50 part, Fructus Crataegi 20-40 part, Aloe 20-40 part, Radix Polygalae 20-30 part, Radix Paeoniae Alba 20-40 part, Radix Bupleuri 20-40 part, Ramulus Cinnamomi 10-20 part, Rhizoma Dioscoreae 20-40 part, Radix Rehmanniae 20-40 part, Radix Notoginseng 20-40 part, Hirudo 20-40 part, Radix Glycyrrhizae Preparata 20-40 part.
Preferably, treat a combination of oral medication for ischemic cerebrovascular, composition and the weight portion of making the crude drug of this medicine are: the Radix Astragali 160 parts, Radix Codonopsis 110 parts, Radix Angelicae Sinensis 90 parts, Herba Cistanches 50 parts, Fructus Crataegi 40 parts, Aloe 40 parts, Radix Polygalae 30 parts, the Radix Paeoniae Alba 30 parts, Radix Bupleuri 30 parts, Ramulus Cinnamomi 20 parts, Rhizoma Dioscoreae 30 parts, Radix Rehmanniae 30 parts, Radix Notoginseng 30 parts, Hirudo 30 parts, Radix Glycyrrhizae Preparata 30 parts.
Preferably, treat a combination of oral medication for ischemic cerebrovascular, composition and the weight portion of making the crude drug of this medicine are: the Radix Astragali 140 parts, Radix Codonopsis 90 parts, Radix Angelicae Sinensis 90 parts, Herba Cistanches 40 parts, Fructus Crataegi 30 parts, Aloe 30 parts, Radix Polygalae 20 parts, the Radix Paeoniae Alba 40 parts, Radix Bupleuri 40 parts, Ramulus Cinnamomi 20 parts, Rhizoma Dioscoreae 40 parts, Radix Rehmanniae 40 parts, Radix Notoginseng 40 parts, Hirudo 40 parts, Radix Glycyrrhizae Preparata 40 parts.
Preferably, treat a combination of oral medication for ischemic cerebrovascular, composition and the weight portion of making the crude drug of this medicine are: the Radix Astragali 100 parts, Radix Codonopsis 80 parts, Radix Angelicae Sinensis 80 parts, Herba Cistanches 30 parts, Fructus Crataegi 20 parts, Aloe 20 parts, Radix Polygalae 20 parts, the Radix Paeoniae Alba 20 parts, Radix Bupleuri 20 parts, Ramulus Cinnamomi 10 parts, Rhizoma Dioscoreae 20 parts, Radix Rehmanniae 20 parts, Radix Notoginseng 20 parts, Hirudo 20 parts, Radix Glycyrrhizae Preparata 20 parts.
Preferably, treat a combination of oral medication for ischemic cerebrovascular, composition and the weight portion of making the crude drug of this medicine are: the Radix Astragali 90 parts, Radix Codonopsis 70 parts, Radix Angelicae Sinensis 60 parts, Herba Cistanches 50 parts, Fructus Crataegi 40 parts, Aloe 20 parts, Radix Polygalae 30 parts, the Radix Paeoniae Alba 20 parts, Radix Bupleuri 30 parts, Ramulus Cinnamomi 30 parts, Rhizoma Dioscoreae 30 parts, Radix Rehmanniae 30 parts, Radix Notoginseng 30 parts, Hirudo 30 parts, Radix Glycyrrhizae Preparata 30 parts.
In a word, the present invention forms monarch, minister, help, make various, and compatibility is rigorous, complements each other, and plays benefiting QI and nourishing blood altogether, the merit of eliminating blood stasis and smoothing collaterals.Can long-term taking for the paracmastic patient of ischemic cerebrovascular, while tonification, carry out admittance.
The preparation method of described combination of oral medication, gets crude drug, adds customary adjuvant, conveniently technique, makes clinical acceptable tablet, granule, pill, capsule, drop pill, slow releasing agent, oral liquid.
The preparation method of described combination of oral medication, gets Radix Notoginseng, the Radix Astragali, Radix Codonopsis, and Rhizoma Dioscoreae powder is broken into powder, sieves, all the other flavour of a drug water extractions 2 times, 1 hour first time, for the second time, 30 minutes, merge decocting liquid, concentrated, mix with fine powder, granule processed, dry, make granule or encapsulated or tabletting.
The preparation method of described combination of oral medication, comprises the steps: that all flavour of a drug are ground into fine powder, sieves, mixing, and granule processed is dry, encapsulated.
Also can adopt with the following method:
The preparation method of described combination of oral medication, comprises the steps: to get Radix Notoginseng, the Radix Astragali, Radix Codonopsis, Rhizoma Dioscoreae powder is broken into powder, sieves, all the other flavour of a drug water extractions 2 times, 1 hour first time, for the second time, 30 minutes, merge decocting liquid, concentrated, the alcohol settling of 50%, filter, reclaim ethanol, mix with fine powder, granule processed, dry, make granule or encapsulated or tabletting.
Detailed description of the invention
Following examples for illustration of the present invention, but are not used for limiting the scope of the invention.
Embodiment 1
1, prescription:
The Radix Astragali 160 grams, Radix Codonopsis 110 grams, Radix Angelicae Sinensis 90 grams, Herba Cistanches 50 grams, Fructus Crataegi 40 grams, Aloe 40 grams, Radix Polygalae 30 grams, the Radix Paeoniae Alba 30 grams, Radix Bupleuri 30 grams, Ramulus Cinnamomi 20 grams, Rhizoma Dioscoreae 30 grams, Radix Rehmanniae 30 grams, Radix Notoginseng 30 grams, Hirudo 30 grams, Radix Glycyrrhizae Preparata 30 grams.
2. method for making:
Get Radix Notoginseng, the Radix Astragali, Radix Codonopsis, Rhizoma Dioscoreae powder is broken into powder, sieves, all the other flavour of a drug water extractions 2 times, 1 hour first time, for the second time, 30 minutes, merges decocting liquid, concentrated, mixes, granule processed with fine powder, dry, makes granule, to obtain final product.
Embodiment 2
1, prescription:
The Radix Astragali 140 grams, Radix Codonopsis 90 grams, Radix Angelicae Sinensis 90 grams, Herba Cistanches 40 grams, Fructus Crataegi 30 grams, Aloe 30 grams, Radix Polygalae 20 grams, the Radix Paeoniae Alba 40 grams, Radix Bupleuri 40 grams, Ramulus Cinnamomi 20 grams, Rhizoma Dioscoreae 40 grams, Radix Rehmanniae 40 grams, Radix Notoginseng 40 grams, Hirudo 40 grams, Radix Glycyrrhizae Preparata 40 grams.
2, technique:
All flavour of a drug are ground into fine powder, sieve, mixing, and granule processed is dry, encapsulated.
Embodiment 3
1, prescription:
The Radix Astragali 100 grams, Radix Codonopsis 80 grams, Radix Angelicae Sinensis 80 grams, Herba Cistanches 30 grams, Fructus Crataegi 20 grams, Aloe 20 grams, Radix Polygalae 20 grams, the Radix Paeoniae Alba 20 grams, Radix Bupleuri 20 grams, Ramulus Cinnamomi 10 grams, Rhizoma Dioscoreae 20 grams, Radix Rehmanniae 20 grams, Radix Notoginseng 20 grams, Hirudo 20 grams, Radix Glycyrrhizae Preparata 20 grams.
2. method for making:
Get Radix Notoginseng, the Radix Astragali, Radix Codonopsis, Rhizoma Dioscoreae powder is broken into powder, sieves, all the other flavour of a drug water extractions 2 times, 1 hour first time, for the second time, 30 minutes, merges decocting liquid, and concentrated, the alcohol settling of 50%, filters, and reclaims ethanol, mixes, granule processed with fine powder, dry, tabletting.
Embodiment 4
1, prescription:
The Radix Astragali 90 grams, Radix Codonopsis 70 grams, Radix Angelicae Sinensis 60 grams, Herba Cistanches 50 grams, Fructus Crataegi 40 grams, Aloe 20 grams, Radix Polygalae 30 grams, the Radix Paeoniae Alba 20 grams, Radix Bupleuri 30 grams, Ramulus Cinnamomi 30 grams, Rhizoma Dioscoreae 30 grams, Radix Rehmanniae 30 grams, Radix Notoginseng 30 grams, Hirudo 30 grams, Radix Glycyrrhizae Preparata 30 grams.
2, method for making:
Get Radix Notoginseng, the Radix Astragali, Radix Codonopsis, Rhizoma Dioscoreae powder is broken into powder, sieves, all the other flavour of a drug water extractions 2 times, 1 hour first time, for the second time, 30 minutes, merges decocting liquid, concentrated, mixes, granule processed with fine powder, dry, makes granule, encapsulated, to obtain final product.
The test of pesticide effectiveness of embodiment 5 Tong Luo Granulae
[test material]
Test medicine: Tong Luo Granulae: chocolate brown powder, is obtained by embodiment 1, is made into required concentration with front distilled water.
Positive control drug: nimodipine, Ruicheng Pharmaceutic Factory, Shanxi Prov, lot number 001102.
[test method and result]
To the protective effect of Cell transplantation rat caused by suture method
By long 40mm, the heating one end of the nylon wire of diameter 0.2mm is smooth spherical.Clean and in apart from 18.5mm place, pommel labelling, be placed in 0.9%NS for subsequent use by wipes of alcohol.The copying and divide into groups of middle cerebral artery occlusion in rat re-perfusion model: get rat 48, be divided into 5 groups at random, sham operated rats 8, all the other respectively group often organize 10.Sham operated rats, model group: give isometric distilled water, positive drug group: give nimodipine 20mg/kg, Tong Luo Granulae high dose group 20g/kg, Tong Luo Granulae low dose group 10g/kg.Each group of oral successive administration 7 days, in last administration after 0.5 hour, uses 10% chloral hydrate, 300mg/kg, intraperitoneal injection of anesthesia.Lie on the back on operating-table, neck medisection, be separated left common carotid (CCA), external carotid artery (ECA), internal carotid artery (ICA), connect with No. 0 line and prick and cut off the branch of ECA, the Lu Wai branch pterygoid process arteria palatina of separation ICA.Folder closes CCA, ICA, and ready nylon embolus is inserted people from ECA, and enter cranium to anterior cerebral artery (ACA) through CCA crotch by ICA, nylon wire insertion depth is about 18mm.Draw nylon wire that its pommel is back to outside during Reperfu-sion can to recover in ECA the blood of middle cerebral artery to supply.It is the same that sham operated rats does not insert nylon wire all the other steps outer.
Result of the test is in table 1.
Table 1 Tong Luo Granulae is on the impact of ischemia-reperfusion rat brain index and brain water content
Note: compare with sham operated rats,
△ △p<0.01
Compare with model group, * * p<0.01
This experimental result shows, Tong Luo Granulae obviously can reduce cerebral index and the brain water content of ischemia-reperfusion rat, obviously extends the breathing time that ligation bilateral common carotid arteries causes acute shallow cerebral mice.The expansible cerebrovascular of Tong Luo Granulae is described, improves cerebral blood flow, improve brain function.
Embodiment 6 toxicity test
[test material]
Test medicine: Tong Luo Granulae: chocolate brown powder, is obtained by embodiment 1, is made into required concentration with front distilled water.
[test method and result]
Acute toxicity test Kunming mouse 18 ± 2g used, male and female half and half.Selection is in good condition after buying this laboratory adaptation 3d, and behavior, movable N/R animal are tested.Fasting 14 ~ 16h before each animals administer, after administration, fasting 4h, can't help water.Single oral gavage administration during experiment, 40mL/kg, wherein blank group gives the distilled water waiting capacity.To the response situation of observation post administration animal, and continuous observation 4h, Continuous Observation 7d. acute toxicity test observation index: observe animal body quality, diet, outward appearance, behavior, secretions, Excreta and poisoning symptom, the initial time of toxic reaction, the order of severity, persistent period, the death condition of record animal, and after distinguishing (D0), administration before administration, the 3rd day (D3), the 7th day (D7) claim the animal scale of construction.
In administration 4h and in 1 week, blank group shows no obvious abnormalities reaction, and all animals have no dead.Each treated animal scale of construction all normally increases, and administration group compares with blank group, no significant difference.This pharmaceutical composition safety non-toxic is described.
Claims (10)
1. treat a combination of oral medication for ischemic cerebrovascular, it is characterized in that the composition of the crude drug making this medicine and weight portion are: Radix Astragali 60-180 part, Radix Codonopsis 40-120 part, Radix Angelicae Sinensis 40-110 part, Herba Cistanches 20-60 part, Fructus Crataegi 10-50 part, Aloe 10-50 part, Radix Polygalae 10-40 part, Radix Paeoniae Alba 10-50 part, Radix Bupleuri 10-50 part, Ramulus Cinnamomi 5-30 part, Rhizoma Dioscoreae 10-50 part, Radix Rehmanniae 10-50 part, Radix Notoginseng 10-50 part, Hirudo 10-50 part, Radix Glycyrrhizae Preparata 10-50 part.
2. a kind of combination of oral medication for the treatment of ischemic cerebrovascular according to claim 1, is characterized in that the composition of the crude drug making this medicine and weight portion are: Radix Astragali 80-160 part, Radix Codonopsis 60-110 part, Radix Angelicae Sinensis 50-100 part, Herba Cistanches 30-50 part, Fructus Crataegi 20-40 part, Aloe 20-40 part, Radix Polygalae 20-30 part, Radix Paeoniae Alba 20-40 part, Radix Bupleuri 20-40 part, Ramulus Cinnamomi 10-20 part, Rhizoma Dioscoreae 20-40 part, Radix Rehmanniae 20-40 part, Radix Notoginseng 20-40 part, Hirudo 20-40 part, Radix Glycyrrhizae Preparata 20-40 part.
3. a kind of combination of oral medication for the treatment of ischemic cerebrovascular according to claim 2, is characterized in that the composition of the crude drug making this medicine and weight portion are: the Radix Astragali 160 parts, Radix Codonopsis 110 parts, Radix Angelicae Sinensis 90 parts, Herba Cistanches 50 parts, Fructus Crataegi 40 parts, Aloe 40 parts, Radix Polygalae 30 parts, the Radix Paeoniae Alba 30 parts, Radix Bupleuri 30 parts, Ramulus Cinnamomi 20 parts, Rhizoma Dioscoreae 30 parts, Radix Rehmanniae 30 parts, Radix Notoginseng 30 parts, Hirudo 30 parts, Radix Glycyrrhizae Preparata 30 parts.
4. a kind of combination of oral medication for the treatment of ischemic cerebrovascular according to claim 2, is characterized in that the composition of the crude drug making this medicine and weight portion are: the Radix Astragali 140 parts, Radix Codonopsis 90 parts, Radix Angelicae Sinensis 90 parts, Herba Cistanches 40 parts, Fructus Crataegi 30 parts, Aloe 30 parts, Radix Polygalae 20 parts, the Radix Paeoniae Alba 40 parts, Radix Bupleuri 40 parts, Ramulus Cinnamomi 20 parts, Rhizoma Dioscoreae 40 parts, Radix Rehmanniae 40 parts, Radix Notoginseng 40 parts, Hirudo 40 parts, Radix Glycyrrhizae Preparata 40 parts.
5. a kind of combination of oral medication for the treatment of ischemic cerebrovascular according to claim 2, is characterized in that the composition of the crude drug making this medicine and weight portion are: the Radix Astragali 100 parts, Radix Codonopsis 80 parts, Radix Angelicae Sinensis 80 parts, Herba Cistanches 30 parts, Fructus Crataegi 20 parts, Aloe 20 parts, Radix Polygalae 20 parts, the Radix Paeoniae Alba 20 parts, Radix Bupleuri 20 parts, Ramulus Cinnamomi 10 parts, Rhizoma Dioscoreae 20 parts, Radix Rehmanniae 20 parts, Radix Notoginseng 20 parts, Hirudo 20 parts, Radix Glycyrrhizae Preparata 20 parts.
6. a kind of combination of oral medication for the treatment of ischemic cerebrovascular according to claim 2, is characterized in that the composition of the crude drug making this medicine and weight portion are: the Radix Astragali 90 parts, Radix Codonopsis 70 parts, Radix Angelicae Sinensis 60 parts, Herba Cistanches 50 parts, Fructus Crataegi 40 parts, Aloe 20 parts, Radix Polygalae 30 parts, the Radix Paeoniae Alba 20 parts, Radix Bupleuri 30 parts, Ramulus Cinnamomi 30 parts, Rhizoma Dioscoreae 30 parts, Radix Rehmanniae 30 parts, Radix Notoginseng 30 parts, Hirudo 30 parts, Radix Glycyrrhizae Preparata 30 parts.
7. the combination of oral medication as described in as arbitrary in claim 1-6, it is characterized in that: get crude drug, add customary adjuvant, conveniently technique, make clinical acceptable tablet, granule, pill, capsule, drop pill, slow releasing agent, oral liquid.
8. the combination of oral medication as described in as arbitrary in claim 1-6, is characterized in that: get Radix Notoginseng, the Radix Astragali, Radix Codonopsis, Rhizoma Dioscoreae powder is broken into powder, sieves, all the other flavour of a drug water extractions 2 times, 1 hour first time, for the second time, 30 minutes, merge decocting liquid, concentrated, mix with fine powder, granule processed, dry, make granule or encapsulated or tabletting.
9. the preparation method of the combination of oral medication as described in as arbitrary in claim 1-6, comprises the steps: that all flavour of a drug are ground into fine powder, sieves, mixing, granule processed, and drying is encapsulated.
10. the preparation method of the combination of oral medication as described in as arbitrary in claim 1-6, comprises the steps:: get Radix Notoginseng, the Radix Astragali, Radix Codonopsis, Rhizoma Dioscoreae powder is broken into powder, sieves, all the other flavour of a drug water extractions 2 times, 1 hour first time, for the second time, 30 minutes, merge decocting liquid, concentrated, the alcohol settling of 50%, filter, reclaim ethanol, mix with fine powder, granule processed, dry, make granule or encapsulated or tabletting.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510960039.2A CN105434790A (en) | 2015-12-21 | 2015-12-21 | Oral pharmaceutical composition used for treating ischemic cerebrovascular disease, and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510960039.2A CN105434790A (en) | 2015-12-21 | 2015-12-21 | Oral pharmaceutical composition used for treating ischemic cerebrovascular disease, and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105434790A true CN105434790A (en) | 2016-03-30 |
Family
ID=55545719
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510960039.2A Pending CN105434790A (en) | 2015-12-21 | 2015-12-21 | Oral pharmaceutical composition used for treating ischemic cerebrovascular disease, and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105434790A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105832803A (en) * | 2016-05-30 | 2016-08-10 | 王政乾 | Medicine with function of treating cerebrovascular diseases, method for preparing medicine and application thereof |
-
2015
- 2015-12-21 CN CN201510960039.2A patent/CN105434790A/en active Pending
Non-Patent Citations (2)
| Title |
|---|
| 谭爱玲等: "养阴柔肝通络法治疗缺血性中风后痉挛30例临床观察", 《江苏中医药》 * |
| 谷井文等: "通脉活络1号方治疗脑梗死恢复期138例总结", 《湖南中医杂志》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105832803A (en) * | 2016-05-30 | 2016-08-10 | 王政乾 | Medicine with function of treating cerebrovascular diseases, method for preparing medicine and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102078520B (en) | Chinese medicinal preparation for treating nervous headache and preparation method thereof | |
| CN103007234B (en) | Traditional Chinese medicine preparation for treating dysmenorrheal caused by endometriosis and preparation method of preparation | |
| CN104958607A (en) | Traditional Chinese medicine composition for treating burning mouth syndromes of climacteric women and preparation method thereof | |
| CN101897821B (en) | Granular preparation for promoting blood circulation, dredging collaterals and relieving pain and preparation method as well as detection method thereof | |
| CN101485867B (en) | Chinese medicinal composition for treating varix and preparation method thereof | |
| CN104547523A (en) | Medicine for enhancing immunity and preparation method thereof | |
| CN105434790A (en) | Oral pharmaceutical composition used for treating ischemic cerebrovascular disease, and preparation method thereof | |
| CN104815232A (en) | Traditional Chinese medicine preparation for treating primary pulmonary hypertension and preparation method thereof | |
| CN102824619B (en) | Pharmaceutical composition for treating ischemic cerebrovascular diseases and preparation method thereof | |
| CN103405574B (en) | Medicinal composition for treating hypertension | |
| CN110237161B (en) | Medicine for treating menopausal syndrome, preparation method and application thereof | |
| CN104983759A (en) | Traditional Chinese medicine composition treating diabetic nephropathy and preparing method thereof | |
| CN105031568A (en) | Postpartum health food and preparation method thereof | |
| CN115192667B (en) | A Chinese medicine composition for improving sexual function and its preparation method and application | |
| CN104001070A (en) | Traditional Chinese medicine composition for treating constipation | |
| CN103690785B (en) | A kind of oral Chinese medicine composition for the treatment of early high blood pressure disease | |
| CN116139236B (en) | Traditional Chinese medicine composition for treating liver depression type insomnia and application thereof | |
| CN105362849A (en) | Method for preparing traditional Chinese medicine composition for treating infertility | |
| CN106511896A (en) | Medicine for cerebral hemorrhage convalescent stage and preparation method of medicine | |
| CN105535658A (en) | Traditional Chinese medicine composition for treating dental ulcer and preparation method thereof | |
| CN105596726A (en) | Composition for preventing and treating sub-health caused by staying up late and preparation method of composition | |
| CN105168537A (en) | Compound medicine for treating bone fracture and preparation method of compound medicine | |
| CN105343309A (en) | Pharmaceutical composition for treating haemorrhoids containing moringa oleifera leaves and preparing method thereof | |
| CN104225475A (en) | Traditional Chinese medicine composition for treating cerebral apoplexy | |
| CN105311419A (en) | Traditional Chinese medicine composition for treating oral inflammations and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160330 |